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Dear Editor, 
 
We resubmit for consideration by the British Journal of Pharmacology our revised manuscript 
entitled “Novel vasocontractile role of the P2Y14 receptor: characterisation of its signaling in 
porcine isolated pancreatic arteries” by Mouhamed Alsaqati, Liaque Latif, Susan L.F. Chan, 
Vera Ralevic. 
 
We have revised the manuscript according to the suggestions provided by the Editor and the 
Reviewers, including the extra experimental data requested, and have responded to the 
comments raised point by point. We have also added new data (western blotting studying the 
level of phosphorylated MLC2 following activation with UDP-glucose and MRS2690 in the 
presence of PPTN) to make the manuscript stronger. In addition, we have changed the name 
of Compound 2 and replaced it by PPTN according to Barrett et al,. (2013) to prevent any 
confusion in the literature. 
  
For all of these reasons we believe that the revised manuscript will be more convincing and 
informative about the novel role of P2Y14 receptors in the vasculature and of interest to 
readers of the British Journal of Pharmacology. 
 
Yours sincerely, 
Authors 
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Background and purpose: The P2Y14 receptor is the newest member of the P2Y receptor 
family; it is Gi/o protein-coupled and is activated by UDP and selectively by UDP-glucose and 
MRS2690 (7-10 fold more potent than UDP-glucose). This study investigated whether the 
P2Y14 receptor is functionally expressed in porcine isolated pancreatic arteries.  
Experimental approach: Pancreatic arteries were prepared for isometric tension recording 
and UDP-glucose, UDP and MRS2690 applied cumulatively after preconstriction with 
U46619, a thromboxane A2 mimetic. Levels of phosphorylated MLC2 were assessed with 
Western blotting. Levels of cAMP were assessed using a competitive enzyme immunoassay 
kit. 
Key results: Concentration-dependent contraction with a rank order of potency of MRS2690 
(10-fold) > UDP-glucose ≥ UDP was observed; contraction was reduced by PPTN, a 
selective antagonist of P2Y14 receptor, which did not affect the response to UTP. Contraction 
to UDP-glucose was not affected by MRS2578, a P2Y6 receptor selective antagonist. In the 
presence of U46619 and forskolin, which increases cAMP levels, contraction to UDP-glucose 
was enhanced. In addition, UDP-glucose and MRS2690 inhibited forskolin-stimulated cAMP 
levels. Removal of the endothelium and inhibition of endothelium-derived contractile agents 
(thromboxane A2, prostaglandin F2α and endothelin-1) inhibited contractions. Y-27632, 
nifedipine and thapsigargin also reduced contraction to the agonists. UDP-glucose and 
MRS2690 increased MLC2 phosphorylation, which was blocked by PPTN.  
Conclusions and implications: These data identify a novel vasocontractile role of P2Y14 
receptors in porcine pancreatic arteries. P2Y14-mediated contraction involves cAMP-
dependent mechanisms, an elevation of Ca
2+
 levels, activation of RhoA/ROCK signalling, 
and MLC2 in porcine pancreatic arteries. It also involves a release of thromboxane A2, 
prostaglandin F2α and endothelin-1.  
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Abbreviations: ATP, Adenosine-5'-triphosphate; HEK, human embryonic kidney; cAMP, 3'-
5'-cyclic adenosine monophosphate; DAG, diacylglycerol; IP3, inositol 1,4,5-triphosphate 
MLC2, myosin light chain 2; NDGA, nordihydroguiaretic acid; PBS, phosphate-buffered 
saline; PGF2α, prostaglandin F2α; PKC, protein kinase C; PPADS, pyridoxalphosphate-6-
azophenyl-2′,4′-disulphonate); PPTN, 4-(4-(Piperidin-4-yl)phenyl)-7-(4-
(trifluoromethyl)phenyl)-2-naphthoic acid; RhoA, ras homolog gene family member A; 
ROCK, Rho-associated protein kinase; SNP,  sodium nitroprusside; UDP, uridine 
diphosphate; UDP-glucose, uridine diphosphate glucose; UTP, uridine-5'-triphosphate. 
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Introduction 
 
P2Y Receptors are members of the superfamily of G-protein coupled receptors (GPCRs); 
they are responsive to purine and pyrimidine nucleotides and nucleotide sugars (ADP, ATP, 
UTP, UDP and UDP-glucose). Eight mammalian subtypes of P2Y receptors have been 
identified: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14 receptors (Abbracchio 
et al., 2006). The P2Y14 receptor was the most recently identified (Chambers et al., 2000). In 
contrast to other P2Y receptors, P2Y14 receptors are activated by nucleotide sugars such as 
UDP-glucose, in addition to UDP-galactose and UDP-glucuronic acid which are less potent 
than UDP-glucose (Abbracchio et al., 2003; Fricks et al., 2008; Harden et al., 2010). They 
are also activated by UDP and MRS2690 (2-thiouridine-5′-diphosphoglucose), which is more 
selective at P2Y14 receptors and 7-10 fold more potent than UDP-glucose (Carter et al., 2009; 
Jacobson et al., 2009; Gao et al., 2010). The P2Y14 receptor is involved in Gi-protein-
mediated signalling, leading to the inhibition of adenylyl cyclase activity and, accordingly, is 
pertussis toxin-sensitive (Jacobson et al., 2009). Gi-protein-derived Gβγ-dimers can initiate 
phospholipase Cβ (PLCβ) signalling pathways, which lead to the stimulation of diacylglycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3) and subsequent activation of RhoA/ROCK 
signalling, protein kinase C (PKC) and myosin light chain (MLC) kinase, besides elevation of 
the intracellular calcium level (Amano et al., 1996; Hartshorne & Gorecka, 2011; Sesma et 
al., 2012).  
 
 Pyridoxalphosphate-6-azophenyl-2′,4′-disulphonate (PPADS) and suramin are non-selective 
antagonists at most of the P2Y receptors, but some P2Y receptors are insensitive to these 
antagonists (Chootip et al., 2005). There is currently no report of antagonist sensitivity of 
P2Y14 receptors for suramin and PPADS. Recently, a novel antagonist at P2Y14 receptors was 
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identified; this antagonist, named 4-(4-(piperidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-
2-naphthoic acid (PPTN)  (Barrett et al., 2013), was characterised in HEK cells through its 
ability to inhibit UDP-glucose-stimulated Ca
2+
 mobilization (Robichaud et al., 2011). In 
addition, it showed good affinity for the P2Y14 receptor (Ki = 1.9 nM in a chimpanzee P2Y14 
binding assay) (Robichaud et al., 2011). When it was studied  in human C6 glioma cells, 
PPTN showed selectivity for P2Y14 receptors with a KB of 434 pM, with no agonist or 
antagonist affinity at P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 or P2Y13 receptors (Barrett et 
al., 2013). 
 
P2Y14 receptor mRNA and protein have a varied expression in the body; they have been 
found in the spleen, placenta, lung, heart, adipose tissue, gastrointestinal smooth muscle,  
endothelial cells, and immune cells (Chambers et al., 2000; Scrivens & Dickenson, 2005; 
Umapathy et al., 2010). Relatively little is known, however, about the functional expression 
of the P2Y14 receptor; best characterised is its role in regulation of the immune system, as a 
number of studies have described an involvement of P2Y14 receptors in modulation of the 
function of human neutrophils and T-lymphocytes, and in secretion of the pro-inflammatory 
cytokine IL-8 in airway epithelial cells (Scrivens & Dickenson, 2005, 2006; Jacobson et al., 
2009). UDP-glucose can be released in a constitutive manner, and during shear stress, to act 
as an extracellular signalling molecule (Lazarowski et al., 2003); its release from multiple 
cell types suggests potentially broad role(s) of the P2Y14 receptor.  
 
Although the exact mechanisms remain to be established, an increase in pancreatic endocrine 
cell activity during hormone secretion corresponds with an increase in blood flow, to meet 
metabolic demand. Thus, alterations in blood flow can influence pancreatic function. The role 
of exogenous purine and pyrimidine di- and triphosphate nucleotides in controlling the 
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functions of endocrine and exocrine components of the pancreas are well described (Novak, 
2008; Burnstock & Novak, 2012). Within the pancreatic vasculature, P2X receptors were 
suggested to mediate vasoconstriction, and P2Y receptors vasodilatation, in response to ATP 
(Hillaire-Buys et al., 1991). P2X1, P2Y2, P2Y4 and P2Y6 receptors, with different 
sensitivities to ATP, UDP and UTP, mediate vasoconstriction in a number of blood vessels 
(Ralevic and Burnstock, 1998), and there is some evidence for a vasocontractile function of 
the P2Y12 receptor (Wihlborg et al., 2004; Högberg et al., 2010). In the current study, we 
describe the pharmacological characterisation of P2Y14 receptor-mediated contractile 
responses of porcine isolated pancreatic artery preparations. A preliminary account of some 
of these data has previously been presented to the British Pharmacological Society (Alsaqati 
et al., 2010). 
 
Materials and methods 
Tissue Preparation 
Pancreases from pigs (either sex, age less than 6 mo, wt ~50 kg) was obtained on ice from a 
local abattoir (G Wood & Sons Ltd, Mansfield). A crude d ssection was conducted to isolate 
the pancreatic arteries (greater pancreatic artery) which were located in the body of the 
pancreas. The vessels were dissected out and placed in Krebs’-Henseleit buffer containing 
2% (w/v) Ficoll (type 70) and refrigerated overnight at 4ºC. The next day, fine dissection was 
performed, and the arteries cut into rings of 0.5 cm in length and suspended in Krebs’-
Henseleit buffer (gassed, 95% O2, 5% CO2).  
The endothelium of some arteries was removed by gently rubbing their innermost surface 
with forceps before attaching it to the setup (Rayment et al., 2007a). Successful removal of 
endothelium was tested using substance P (10 nM). Endothelium-denuded arteries relaxed in 
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response to substance P to less than 10% of the U46619 (11α,9α-epoxymethano-PGH2) 
induced contraction, while in endothelium-intact arteries the relaxation to substance P was 
36% ± 8 (n=7, data not shown). 
 
Responses in the porcine isolated pancreatic artery 
 
Arterial rings were mounted onto wires in tissue baths (20 ml) containing warm (37°C), 
oxygenated Krebs’-Henseleit solution and were connected via isometric force transducers 
(ADInstruments, Sydney, Australia), to a PC running the computer program LabChart 
(ADInstruments, Sydney, Australia). Rings were put under tension (15 g) and allowed to 
equilibrate for 60 min before assessing viability with two challenges of 75 mM potassium 
chloride (KCl). The tissues were then allowed to equilibrate for 60 min, after which U46619 
(10 - 100 nM), a thromboxane A2 mimetic, was used to contract the tissues to between 40-
80% of the second KCl response. This ensured that if there was a vasodilator component to 
the response, for example due to activation of multiple P2 receptor subtypes, this could be 
detected. Once an appropriate level of U46619 response had been achieved, cumulative 
addition of UDP-glucose, UDP or MRS2690 were applied. Antagonists or inhibitors were 
applied 10 min prior to the addition of U46619, allowing incubation with the tissues for a 
minimum of 30 min prior to the application of agonists. Desensitisation of the contraction to 
UDP-glucose was generated by exposing the arteries to UDP or UDP-glucose 10 min prior 
the addition of U46619. An exception to preconstriction with U46619, were experiments with 
L-655,240 (1-[(4-Chlorophenyl)methyl]-5-fluoro--α,α,3-trimethyl-1H-indole-2-propanoic 
acid), in which arteries were preconstricted with endothelin-1. In experiments using dimethyl 
sulfoxide (DMSO) as the solvent (see reagents and drugs section), DMSO was added to the 
arteries (vehicle control). 
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Effect of forskolin on subsequent UDP-glucose or UTP responses 
Tissues were exposed to U46619 (10 - 100 nM) and relaxed with forskolin (1 µM), involving 
elevation of cAMP, back to the baseline; cumulative concentration-response curves were then 
constructed for UDP-glucose (1 µM – 1 mM) or UTP (10 µM – 1 mM). Responses to UDP-
glucose or UTP obtained under these conditions were compared to control responses in which 
drugs were added at basal tone without exposing to either U46619 or forskolin. The tissue 
was allowed to recover for 20 min before a concentration-response curve to UDP-glucose or 
UTP was constructed. 
Western blotting 
Segments of porcine pancreatic arteries were set up in the organ baths and tensioned to 15 g, 
then left for approximately 60 min to reach a new baseline of resting tension. Tissues were 
incubated with 100 µM UDP-glucose for 30, 60, 120, 180, 240 and 300 s. In addition, in 
other experiments, the tissues were incubated with UDP-glucose (100 µM) or MRS2690 (10 
µM) for 30 s in the presence or absence of PPTN. Segments were quickly removed from the 
organ baths and immediately frozen on dry ice. Control tissues were not exposed to any 
compound (basal conditions). Segments were then homogenised in lysis buffer (20 mM Tris, 
1 mM EGTA, 0.1% (v/v) Triton X100, 1 mM NaF, 10 mM beta glycerophosphate, pH 7.6), 
containing protease inhibitor cocktail tablets, EDTA free. Samples with solubilisation buffer 
6×SB: (24% (w/v) sodium dodecyl sulphate, 30% (v/v) glycerol, 5% (v/v) beta 
mercaptoethanol, 2.5% (v/v) bromophenol blue, 1.5M Tris HCl, pH 6.8 ) were heated at 95°C 
for 5 min. Subsequently, electrophoresis was carried out on 4-20% Tri-Glycine (PAGE) Gold 
Precast Gels (Bio-Rad, Hercules, CA, U.S.A.), 15 µg protein per lane. Samples were 
transferred to nitrocellulose membranes. Next, blots were incubated in blocking solution (5% 
(w/v) powdered milk in Tris-buffered saline containing 0.1% (v/v) Tween 20) for 60 min, at 
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room temperature. Blots were incubated overnight at 4°C with primary antibody against 
phosphorylated myosin light chain kinase 2 (MLC2, 1:500) or total (MLC2, 1:1000) diluted 
in blocking solution. After washing in Tris buffered saline containing 0.1% (v/v) Tween 20, 
the blots were incubated with an appropriate IRDye
®
-conjugated secondary antibody (LI-
COR). Proteins were visualised using the Licor/Odyssey infrared imaging system 
(Biosciences, Biotechnology). Bands were analyzed by densitometry using the Odyssey 
application software and expressed as phosphorylated MLC2 normalised to total MLC2. For 
investigating the existence of P2Y14 receptor in pancreatic arteries, untreated samples were 
homogenised and examined as explained above. 
 
cAMP measurement in porcine pancreatic arteries 
 
Pancreatic artery rings were stimulated with 75 mM KCl followed by U46619 (10 nM) and 
forskolin (1 µM), and then the arteries were challenged for 3 min with UDP-glucose (1 mM), 
MRS2690 (10 µM), UTP (1 mM) or distilled water (control group). Pancreatic rings were 
collected and immediately frozen on dry ice and then stored in vials at -80 C until their study. 
The tissues were homogenised in 5% (w/v) trichloroacetic acid (TCA) in water with a 
borosilicate glass, homogeniser, and then centrifuged for 10 min at 1500 g. TCA was 
extracted from the supernatant samples using water-saturated ether, and evaporated for 5 min 
to remove the residual ether from the aqueous fractions. Samples were diluted (1:2) in ether-
extracted 5% (w/v) TCA. cAMP concentration was measured using a competitive enzyme 
immunoassay kit (Cayman Chemical Co., Ann Arbor, MI). The working range of the cAMP 
assay was 0.1–1000 pmol/ml. cAMP concentration was expressed as a percentage of 
forskolin-induced [cAMP] elevation.  
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Reagents and Drugs 
Krebs’-Henseleit buffer was composed of the following (mM); NaCl 118, KCl 4.8, 
CaCl2.H2O 1.3, NaHCO3 25.0, KH2PO4 1.2, MgSO4.7H2O 1.2 and glucose 11.1. Suramin, 
NDGA, nifedipine, thapsigargin, UTP, U46619, sodium nitroprusside (SNP), zafirlukast, 
BQ788 (N-cis-2,6-dimethylpiperidinocarbonyl-L-gmethylleucyl-D-1-methoxycarboyl-D-
norleucine), UDP-glucose and UDP were purchased from Sigma (Poole, Dorset, UK), while 
DUP 697, MRS2578 (N,N″-1,4-butanediyl bis(N′-[3-isothiocynatophenyl)] thiourea), PPADS 
and substance P, MRS2690, L-655,240, endothelin-1, BQ123 (cyc(DTrp-DAsp-Pro-D-Val-
Leu)), Y-27632 (trans-4-[(1R)-1-aminoethyl]-N-4-pyridinyl-cyclohexane carboxamide) and 
forskolin were from Tocris Biosciences Ltd. (Bristol, UK). PPTN, a selective high affinity 
antagonist of P2Y14 receptor, was kindly gifted from Merck Frosst Centre for Therapeutic 
Research. Primary antibodies for Western blotting were purchased from Cell Signalling 
Technology for phosphorylated MLC2 antibody, (cat no. 3674S) and total MLC2 antibody, 
(cat no. 3672). Cyclic AMP EIA kit (cat No. 581001) was purchased from Cayman Chemical 
Company, (Ann Arbor, MI). U46619 was dissolved in ethanol at 10 mM stock concentration. 
DUP 697, PPTN, BQ788, MRS2578, L-655,240, nifedipine, thapsigargin, zafirlukast and 
forskolin were dissolved in DMSO. All other drugs were dissolved in distilled water. All 
reagents and drugs nomenclature conformed to BJP's Guide to Receptors and Channels 
(Alexander et al., 2011). 
 
Data Analysis 
Data were expressed as log concentration-response plots. The contraction to all agonists was 
expressed in g, and measured from the stabilised U46619 response. Values for all figures 
refer to mean ± S.E.M with 95% confidence. Results were compared by two-way ANOVA or 
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Student’s unpaired t-test (Prism, GraphPad, San Diego, CA, USA). Differences were 
considered to be significant when the P value was < 0.05. N expresses the number of animals. 
 
Results 
Effect of UDP-glucose, UDP and MRS2690 in porcine isolated pancreatic arteries 
To investigate the possible functional expression of P2Y14 receptors and their role in porcine 
pancreatic arteries, agonists for this receptor were applied as cumulative concentrations. 
MRS2690, a selective P2Y14 receptor agonist (0.1 µM to 30 µM), UDP-glucose (1 µM to 1 
mM) and UDP (1 µM to 1 mM) were added after preconstriction with U46619. All of the 
agonists induced a concentration-dependent contraction with a rank order of potency of 
MRS2690 > UDP-glucose ≥ UDP.  MRS2690 was significantly more potent, by 
approximately 10-fold, than UDP-glucose (P < 0.01, two-way ANOVA, Figure 1A), while 
UDP-glucose and UDP responses were equipotent (Figure 1A). Both UDP-glucose and UDP 
(P2Y14 receptor agonists) separately induced significant attenuation of the contraction to 
UDP-glucose; for instance, the response to 100 µM UDP-glucose was decreased by 55 ± 7% 
in the presence of 100 µM UDP-glucose, and by 53 ± 7% in the presence of 100 µM UDP (P 
< 0.001, n=10-13, Figure 1B). 
 
Effect of PPADS and suramin on responses to UDP-glucose, UDP and MRS2690 in 
porcine isolated pancreatic arteries 
Responses to UDP-glucose, UDP and MRS2690 were characterised using the non-selective 
P2 receptor antagonists PPADS (10 µM) and suramin (100 µM) (Rayment et al., 2007b). 
Both PPADS and suramin significantly enhanced the contractions evoked by UDP-glucose 
and UDP (Figure 2A, 2B). The contraction to 100 µM UDP-glucose was enhanced by 121 ± 
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38% (P < 0.001, n=7) and by 100 ± 23% (P < 0.001, n=8) in the presence of PPADS and 
suramin respectively (Figure 2A). The contraction to 1 mM UDP was enhanced by 180 ± 
46% (P < 0.001, n=8), and by 154 ± 30% (P < 0.001, n=8) in the presence of PPADS and 
suramin respectively (Figure 2B). Suramin and PPADS failed to alter the contraction to 
MRS2690 (Figure 2C). In contrast, suramin and PPADS blocked the contraction to UTP, a 
P2Y2 and P2Y4 receptors agonist (von Kügelgen, 2006) (unpublished observations). UDP is a 
ligand at P2Y6 receptors as well as P2Y14 receptors. Therefore, the effect of UDP was 
examined in the presence of MRS2578 (10 µM), a P2Y6 receptor selective antagonist 
(Mamedova et al., 2004). The contraction evoked by UDP was unaffected at lower 
concentrations but was augmented at higher concentrations of UDP (supplementary 
information), while MRS2578 did not alter the responses to UDP-glucose or MRS2690 
(supplementary information).  
 
Effect of PPTN, a selective high affinity antagonist of P2Y14 receptor, on responses to 
UDP-glucose and MRS2690 in porcine isolated pancreatic arteries 
The responses to UDP-glucose and MRS2690 were examined in the presence of PPTN (1 
µM), a selective high affinity antagonist of P2Y14 receptor (Robichaud et al., 2011; Barrett et 
al., 2013). This compound significantly reduced the contraction evoked by UDP-glucose at 
basal tone (Supplementary information) and that by UDP-glucose and MRS2690 at raised 
tone (Figure 3A, 3B). PPTN inhibited the contraction to 100 µM UDP-glucose and to 10 µM 
MRS2690 by 55 ± 10% (P < 0.05, n=7) and by 46 ± 9% (P < 0.01, n=9) respectively (Figure 
3A, 3B). The contraction to UTP was not altered in the presence of PPTN (Figure 3C). 
Typical traces, showing the effect of MRS2690 in the absence and in the presence of PPTN, 
are shown in Figure 3D. 
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Effect of endothelium removal on responses to UDP-glucose, UDP and MRS2690 in 
porcine isolated pancreatic arteries 
The responses of UDP-glucose, UDP and MRS2690 were studied after the endothelium had 
been removed. The contractions induced by UDP-glucose, UDP and MRS2690 were 
significantly attenuated in the endothelium-denuded arteries (Figure 4). Removal of 
endothelium reduced the contractions to 1 mM UDP-glucose by 50 ± 7% (P < 0.001, n=12), 
that to 1 mM UDP by 61±11% (P < 0.001, n=15) and that to 30 µM MRS2690 by 41 ± 5% (P 
< 0.01, n=5) (Figure 4). 
 
Effect of DUP 697 on responses to UDP-glucose, UDP and MRS2690 in porcine isolated 
pancreatic arteries 
Because the contractions to P2Y14 receptor agonists were mainly endothelium-dependent, 
these were studied in the presence of DUP 697, a cyclooxygenase-2 (COX-2) inhibitor, since 
COX-2 facilitates the release of agents which are responsible for endothelium-dependent 
contraction. DUP 697 (3 µM) diminished the responses to UDP-glucose, UDP and MRS2690 
to a similar extent as removal of the endothelium (Figure 5), while DUP 697 did not alter the 
contraction to U46619 (the preconstriction agent) or the contraction to ATP (data not shown). 
DUP 697 reduced the contraction to 1 mM UDP-glucose by 34 ± 10% (P < 0.001, n=11), that 
to 1 mM UDP by 38 ± 7.5% (P < 0.001, n=15) and that to 30 µM MRS2690 by 22.5 ± 13% 
(P < 0.01, n=4), (Figure 5).  
 
The role of endothelium-derived contracting factors in the response to UDP-glucose in 
porcine isolated pancreatic arteries 
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The following experiments were carried out using mainly UDP-glucose or UDP due to the 
cost considerations involved with use of MRS2690. The possible involvement of 
thromboxane A2, leukotrienes, endothelin-1 and PGF2α, which can be released from 
endothelial cells (Mombouli & Vanhoutte, 1993; Kurahashi et al., 2003; Wong et al., 2009), 
in endothelially-mediated contraction to UDP-glucose was investigated. The contraction to 
UDP-glucose was not altered in the presence of nordihydroguaiaretic acid (NDGA) (10 µM), 
a lipoxygenase inhibitor (Figure 6A) or zafirlukast (10 µM), a leukotriene receptor inhibitor 
(Figure 6B). The contraction to UDP-glucose was reduced in the presence of BQ123 (1 µM), 
a selective ETA receptor antagonist; the response to 100 µM UDP-glucose was attenuated by 
10 ± 3% (P < 0.05, n=14) in the presence of BQ123 (Figure 6C), which was only effective 
with intact endothelium (Supplementary information). The contraction to UDP-glucose was 
unaltered in the presence of BQ788 (1 µM), a selective ETB receptor antagonist 
(Supplementary information). In addition, UDP-glucose induced-contraction was reduced in 
the presence of L-655,240 (1 µM), a selective thromboxane A2/prostaglandin endoperoxide 
receptor antagonist. The response to 100 µM UDP-glucose was inhibited by 38 ± 5% (P < 
0.001, n=9) in the presence of L-655,240 (Figure 6D). These data indicate that UDP-glucose 
mediated-contraction occurs mainly via thromboxane and prostaglandins, with a lesser 
involvement of endothelin-1. 
 
Effect of inhibition of calcium release and calcium entry on the response to UDP-glucose 
and UDP in porcine isolated pancreatic arteries 
Binding of agonist to the recombinant P2Y14 receptor leads to increase Ca
2+
 flux in some 
cells (Skelton et al., 2003; Gao et al., 2010). To test this in porcine pancreatic arteries, 
responses to UDP-glucose and UDP were examined in the presence and absence of nifedipine 
(1 µM), an L-type voltage-gated calcium channel blocker, and thapsigargin (100 nM), a 
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potent inhibitor of sarco-endoplasmic reticulum Ca
2+
-ATPases which leads to depletion of 
intracellular calcium. Both of these inhibitors reduced the contraction evoked by 100 µM 
UDP-glucose, by 39 ± 5% (P < 0.001, n=15) in the presence of nifedipine, and by 25 ± 8% (P 
< 0.05, n=12-15) in the presence of thapsigargin (Figure 7A, 7B). Responses to 100 µM UDP 
were inhibited by 53 ± 2% (P < 0.001, n=9) in the presence of nifedipine, and by 36 ± 6% (P 
< 0.001, n=9) in the presence of thapsigargin (data not shown). Typical traces showing the 
effect of UDP-glucose in the absence and in the presence of nifedipine are shown in Figure 
7C. 
 
Effect of inhibition of the Rho-kinase pathway on the responses to UDP-glucose, UDP 
and MRS2690 in porcine isolated pancreatic arteries 
Following the activation of P2Y14 receptors, MLC may be phosphorylated because of 
upstream stimulatory RhoA/ROCK signalling (Amano et al., 1996; Hartshorne & Gorecka, 
2011). To test the possible involvement of this pathway, experiments were conducted to 
study the contractions to UDP-glucose, UDP and MRS2690 in the presence of Y-27632 (5 
µM), a selective inhibitor of the Rho-associated protein kinase p160ROCK. Y-27632 
significantly inhibited the contraction evoked by UDP (Figure 8A), MRS2690 (Figure 8B) 
and UDP-glucose (data not shown). For instance, the response to 300 µM UDP was reduced 
by 50± 4% (P < 0.001, n=15, Figure 8A), that to 30 µM MRS2690 by 50 ± 15% (P < 0.001, 
n=9, Figure 8B) and that to 1 mM UDP-glucose by 52 ± 8% (P < 0.001, n=9, data not 
shown). The response to UDP-glucose was associated with an increase in the level of MLC2 
phosphorylation, after 30–60 s of treatment with 100 µM UDP-glucose, and returned to the 
basal level of phosphorylated MLC2 from 120-300s (Figure 8C), which suggested an 
involvement of MLC2 activation in the response to UDP-glucose P2Y14 receptor signalling 
pathway. The ability of UDP-glucose (100 µM) or MRS2690 (10 µM) to elevate the MLC2 
Page 16 of 51
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
 
phosphorylation (after 30 s of treatment) was abolished in the presence of PPTN (1 µM), 
which shows that the ability of UDP-glucose or MRS2690 to elevate MLC2 phosphorylation 
in porcine pancreatic arteries is mediated by P2Y14 receptors (Figure 9). 
 
 
Effect of pre-constriction with U46619, and relaxation with forskolin, on the response to 
UDP-glucose in porcine isolated pancreatic arteries 
Agonist-promoted activation of Gi and subsequent inhibition of adenylyl cyclase is one of the 
signalling responses of P2Y14 receptors. Therefore, the response to UDP-glucose was tested 
after exposure to U46619 and subsequent relaxation by forskolin (back to the baseline), 
involving elevation of intracellular cyclic AMP. UDP-glucose induced a greater contraction 
compared with the control, in which UDP-glucose was applied at basal tone without the 
tissues being exposed to U46619 or forskolin (Figure 10). The contraction to 100 µM UDP-
glucose was enhanced by 930 ± 108% (P < 0.001, n=11) after the exposure to U46619 and 
forskolin (Figure 10A). In contrast, when responses to UTP, an agonist at P2Y2 and P2Y4 
receptors (Gq protein coupled receptors) were investigated in vessels exposed to U46619 and 
forskolin, there was no change in the contractions (Figure 10B). In addition, the response to 
UDP-glucose was not altered after contraction with U46619 and relaxation with SNP (100 
µM), which elevates intracellular cyclic GMP (Roberts et al., 1999). Typical traces showing 
the effect of UDP-glucose on basal tone and after the tissues had been contracted by U46619 
and then relaxed with forskolin are shown in Figure 10C. 
 
Effect of UDP-glucose and MRS2690 on the cAMP level in porcine isolated pancreatic 
arteries 
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On the basis that cAMP is involved in the contraction to P2Y14 receptor agonists, we 
measured the cellular levels of this second messenger in pancreatic artery rings. We 
investigated the effects of UDP-glucose, MRS2690 and UTP (as a control, since it is coupled 
to Gq protein) on cAMP level in the presence of U46619 + forskolin (to mimic the raised tone 
condition of the pharmacology experiments). UDP-glucose (1 mM) and MRS2690 (10 µM) 
induced a significant decrease in cAMP level in relative to the control (*P < 0.05, n=4), while 
UTP had no significant effect on cAMP levels (Figure 11). 
 
Discussion 
The current study presents evidence for the functional expression of contractile P2Y14 
receptors, sensitive to the endogenous nucleotides UDP-glucose and UDP in arteries of pig 
pancreas. Evidence from the contractile studies and the cAMP immunoassay is consistent 
with the ability of this receptor to inhibit adenylyl cyclase, while immunoblotting indicates 
the downstream involvement of MLC2. The contractile response was mediated largely by the 
endothelium with an involvement of endothelin, thromboxane A2 and PGF2α. 
 
Contractile studies showed that contractions to UDP-glucose and UDP were almost 
equipotent, whereas the contraction to MRS2690, a selective P2Y14 receptor agonist, was 
approximately 10-fold more potent than that of UDP-glucose at the P2Y14 receptor (Figure 
1A). This is consistent with previous reports which suggest a 7-10 fold greater potency of 
MRS2690 over UDP-glucose (Jacobson et al., 2009;  Gao et al., 2010). MRS2690 activity 
was observed at ≤ 10 µM; at 10 µM MRS2690 has been reported to be inactive at P2Y2 
receptors (Ko et al., 2009). 
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PPTN is a non-nucleotide, high affinity competitive antagonist at P2Y14 receptors. It was 
assessed in HEK cells using a calcium mobilization assay and it inhibited UDP-glucose 
mediated signalling, and showed no effect on other P2Y receptors at concentrations up to 10 
µM (Robichaud et al., 2011; Barrett et al., 2013). The responses to the P2Y14 receptor 
agonists were examined in the presence of this antagonist. PPTN blocked the contractions 
induced by UDP-glucose and MRS2690 which confirms the involvement of P2Y14 receptors 
in our arteries (Figure 3A, 3B).  
The responses to the P2Y14 receptor agonists were examined in the presence of the non-
selective P2 receptor antagonists, suramin and PPADS. The non-selective antagonists 
induced a small increase in the contractions to UDP and UDP-glucose (Figure 2A, 2B). 
However, they failed to change the response to MRS2690 (Figure 2C). The lack of effect of 
suramin and PPADS appears to rule out an involvement of P2Y2 and/or P2Y4 receptors, since 
we have shown that they blocked the responses to UTP in porcine pancreatic arteries 
(unpublished observations) and other tissues (Rayment et al., 2007b).  It is unclear why these 
antagonists enhanced the effects of P2Y14 receptor agonists. However, it is clear that suramin 
and PPADS had different effect on UTP responses versus responses of MRS2690 and UDP-
glucose indicating actions at different receptors. 
Contractile responses to UDP-glucose, UDP and MRS2690 were significantly inhibited after 
the endothelium was removed (Figure 4), which indicated that the main expression of P2Y14 
receptor may be on the endothelial layer of porcine pancreatic arteries. Similarly, the P2Y14 
receptor has been reported to be expressed in endothelial cells of porcine coronary artery, 
human lung microvascular endothelial cells, and pulmonary artery vasa vasorum endothelial 
cells (Umapathy et al., 2010; Abbas et al., 2011; Lyubchenko et al., 2011). P2Y14 receptor 
expression was barely detectable in mouse thoracic aorta (Kauffenstein et al., 2010); in 
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contrast, rat aortic smooth muscle cells show robust expression of the receptor, as observed in 
freshly isolated and cultured cells (Govindan et al., 2010). 
To investigate the mechanism underlying the contraction mediated by P2Y14 receptors in 
pancreatic arteries, responses to UDP-glucose, UDP and MRS2690 were examined in the 
presence of DUP 697. As seen in Figure 5, the endothelium-dependent contractions were 
attenuated in the presence of the selective COX-2 inhibitor. Endothelial cells can release 
contractile factors (EDCFs), which may include thromboxane A2, PGF2α, leukotrienes and 
endothelin-1. Thromboxane A2 and PGF2α are released from the endothelium due to the 
activity of cyclooxygenase-2 (Mombouli & Vanhoutte, 1993; Wong et al., 2009). To 
characterise EDCFs involved in the contraction to UDP-glucose, experiments were conducted 
to study the responses to UDP-glucose in the presence of zafirlukast, BQ123, BQ788 and L-
655,240. Only BQ123 and L-655,240 were able to inhibit the contraction evoked by UDP-
glucose which indicated an involvement of thromboxane A2, prostaglandins and endothelin-1 
(Figure 6). These agents, after being released from the endothelium, may act on their 
receptors on vascular smooth muscle cells (Wong et al., 2009). 
The involvement of extracellular calcium influx and calcium released from sarcoplasmic 
reticulum (SR) as a part of the response to P2Y14 receptors activation has been reported 
(Verin et al., 2011). In addition, calcium-induced release of calcium from SR and influx of 
external Ca
2+ 
in excitation-contraction in response to some activated receptors have been also 
reported (Fabiato, 1983; Li et al., 2003). In porcine pancreatic arteries, contractions to UDP-
glucose (Figure 7A, B) and UDP (data not shown) were significantly decreased in the 
presence of nifedipine or thapsigargin, which identified an involvement of elevated 
intracellular calcium level. Collectively, our results suggest that when UDP-glucose, UDP 
and MRS2690 act at the P2Y14 receptors, which are expressed mainly on the endothelium, the 
intracellular Ca
2+
 levels may be elevated; this may then activate endothelin-1 and 
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phospholipase A2 which liberates arachidonic acid, which is then converted by the activity of 
COX-2 to produce the contractile agents, thromboxane A2 and prostaglandin, which bind to 
receptors on vascular smooth muscle cells to induce contraction.  
 
A number of studies have considered the signalling mechanism underlying the functional 
response of P2Y14 receptors (Harden et al., 2010; Sesma et al., 2012). Recent reports claimed 
that UDP-glucose promotes concentration-dependent activation of RhoA in isolated human 
neutrophils (Sesma et al., 2012). This was tested in porcine pancreatic arteries when 
responses were investigated in the presence of Y-27632; this compound inhibited the 
contraction evoked by UDP-glucose, UDP and MRS2690 (Figure 8A, 8B), which showed an 
involvement of RhoA in the response to P2Y14 receptor agonists. Activation of RhoA leads to 
phosphorylation of MLC and subsequently contraction of arteries in a calcium-independent 
manner (Amano et al., 1996; Hartshorne & Gorecka, 2011). Accordingly, when UDP-glucose 
or MRS2690 were incubated with the tissues, the level of phosphorylated MLC2 was 
elevated, but this elevation was abolished in the presence of PPTN, confirming that it is 
happening through the activation of P2Y14 receptors (Figure 8C, 9). 
It is well established that the P2Y14 receptor is coupled to Gi protein, leading to the inhibition 
of forskolin-stimulated adenylyl cyclase activity, and hence inhibition of the cyclic AMP 
level. Accordingly, the P2Y14 receptor is pertussis toxin-sensitive (PTX) (Jacobson et al., 
2009). It is notoriously difficult to successfully block Gi coupled receptors with PTX in 
isolated blood vessels, as we have also found. However, in tissues which had been 
preconstricted with U46619 and relaxed with forskolin (to elevate the cAMP levels), 
subsequent addition of UDP-glucose produced a significantly greater contraction compared 
with the controls (UDP-glucose added at basal tone, or UTP applied after preconstriction with 
U46619 and relaxation with forskolin) (Figure 10), consistent with an involvement of Gi 
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coupled receptors. Other purine receptors, namely P2Y1, P2Y2, P2Y4, P2Y6 receptors, are 
generally Gq protein-coupled. Furthermore, relaxation with SNP (to elevate cGMP levels) 
after preconstriction with U46619 had no effect on the contractile response to UDP-glucose 
(data not shown). These findings together with the data obtained from cAMP assay (Figure 
11) indicate that the enhanced contraction to UDP-glucose is mainly dependent on the 
agonist's ability to lower cyclic AMP levels.  
Reduction in pancreatic blood flow has been observed in acute and chronic pancreatitis and 
some other pancreatic diseases (Satoh et al., 2000; Nguyen et al., 2010), implicating 
pancreatic tissue perfusion as an important factor in pathogenesis of pancreatic diseases and 
symptoms. There is increasing evidence for the role of purinergic signalling in the 
pathophysiology of the pancreas (Burnstock & Novak, 2012). Drugs designed to target 
specific component of purinergic system may be of relevance to the management of 
pancreatitis, cystic fibrosis, pancreatic cancer and diabetes. 
In conclusion, this study has shown a novel vasocontractile action of UDP-glucose which 
appears to be mediated by the P2Y14 receptor in porcine isolated pancreatic arteries. P2Y14 
receptors induce contraction via an involvement of endothelin-1, thromboxane A2 and 
prostaglandins released from the endothelium. In addition, P2Y14-mediated contraction 
involves the activation of Rho kinase, and the subsequent phosphorylation of MLC2. The 
ability of P2Y14-receptor agonist to inhibit cAMP level indicates P2Y14 receptor coupling to 
Gi proteins. This study identifies a novel role for the P2Y14 receptor as a vasocontractile P2 
receptor. 
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Figure Legends 
 
Figure 1. (A) Concentration-dependent contractions evoked by UDP-glucose, UDP and 
MRS2690 in U46619-preconstricted porcine pancreatic arteries (**P < 0.01, two-way 
ANOVA, MRS2690 response vs UDP-glucose and UDP responses, F=13.74, 16.03; n=9-12). 
(B). Attenuation of UDP-glucose-induced contraction (the control) in the presence of UDP-
glucose (100 µM) and UDP (100 µM) (added 10 min prior to U46619 addition). Both UDP-
glucose and UDP significantly attenuated the contraction evoked by UDP-glucose (***P < 
0.001, two-way ANOVA, UDP-glucose contraction in the absence or presence of UDP-
glucose or UDP, F=63.11, 56.48; n=10-13). Data are presented as mean ± SEM. 
 
Figure 2. Effect of PPADS (10 µM) and suramin (100 µM) on responses to (A) UDP-
glucose, (B) UDP, and (C) MRS2690 in U46619-preconstricted porcine pancreatic arteries. 
(A) Suramin and PPADS enhanced the effects of UDP-glucose (***P < 0.001, two-way 
ANOVA, UDP-glucose with suramin or PPADS vs UDP-glucose alone, F=19.85, 23.07; 
n=6-10). (B) Suramin and PPADS enhanced the effects of UDP (***P < 0.001, two-way 
ANOVA, UDP with suramin or PPADS vs UDP alone, F=16.83, 45.24; n=8-16). (C) 
Suramin and PPADS had no effect on the contraction to MRS2690 (n=5-9). Data are 
presented as mean ± SEM.  
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Figure 3. Effect of PPTN (1 µM), a P2Y14 receptor antagonist, on responses to (A) UDP-
glucose, (B) MRS2690, (C) UTP in U46619-preconstricted porcine pancreatic arteries. (A) 
PPTN inhibited the effect of UDP-glucose (*P < 0.05, two-way ANOVA, F=6.56; n=7). (B) 
PPTN inhibited the effect of MRS2690 (**P < 0.01, two-way ANOVA, F=12.85; n=9). (C) 
PPTN had no effect on the response to UTP (n=8-10). Data are presented as mean ± SEM. 
(D) Typical traces showing the effect of MRS2690 in the absence and in the presence of 
PPTN.  
 
Figure 4. Effect of removal of the endothelium on responses to (A) UDP-glucose, (B) UDP, 
(C) MRS2690, in U46619-preconstricted porcine pancreatic arteries. The removal of 
endothelium reduced the contractions evoked by (A) UDP-glucose, (B) UDP, (C) MRS2690 
(**P < 0.01, ***P < 0.001, two-way ANOVA, F=8.15, 51.24, 9.48; n=4-15). Data are 
presented as mean ± SEM. 
 
Figure 5. Effect of DUP 697 (3 µM) on responses to (A) UDP-glucose, (B) UDP, (C) 
MRS2690 in U46619-preconstricted porcine pancreatic arteries. DUP 697 inhibited the 
contractions evoked by (A) UDP-glucose, (B) UDP, (C) MRS2690 (** P < 0.01, *** P < 
0.001, two-way ANOVA, F=7.85, 35.31, 4.95; n=4-15). Data are presented as mean ± SEM. 
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Figure 6. The contraction evoked by UDP-glucose in the presence of (A) NDGA (10 µM), 
(B) BQ123 (1 µM), (C) zafirlukast (10 µM) in U46619-preconstricted porcine pancreatic 
arteries, (D) L-655,240 (1 µM) in endothelin-1-preconstricted porcine pancreatic arteries. 
(A), (C) NDGA and zafirlukast did not alter the response to UDP-glucose (n=7-10). (B), (D) 
BQ-123 and L-655,240 inhibited the response evoked by UDP-glucose (*P < 0.05, ***P < 
0.001, two-way ANOVA, F=4.97, 19.03;  n=9-14). Data are presented as mean ± SEM. 
 
Figure 7. Effect of (A) nifedipine (1 µM) and (B) thapsigargin (100 nM) on the response to 
UDP-glucose in U46619-preconstricted porcine pancreatic arteries. Both inhibitors, 
nifedipine and thapsigargin, inhibited the contraction evoked by UDP-glucose (*P < 0.05, 
***P < 0.001, two-way ANOVA, F=32.5, 5.84; n= 9-13). Data are presented as mean ± 
SEM. (C) Typical traces showing the responses of UDP-glucose in the absence and in the 
presence of nifedipine.  
 
Figure 8. Effect of Y-27632 (5 µM), a selective inhibitor of the Rho-associated protein 
kinase on responses to (A) UDP, (B) MRS2690 in U46619-preconstricted porcine pancreatic 
arteries. Y-27632 reduced the contraction to (A) UDP, (B) MRS2690 (***P < 0.001, two-
way ANOVA, F=53.07, 10.32; n=9-15). Data are presented as mean ± SEM. (C) MLC2 
phosphorylation induced by 100 µM UDP-glucose in porcine pancreatic arteries. A time-
course (above) and a representative blot (below) of phospho- (green) and total- (red) MLC2 
(*P < 0.05, one-way ANOVA, n=4).  
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Figure 9. PPTN, a selective high affinity antagonist of P2Y14 receptor, abolished the ability 
of UDP-glucose and MRS2690 to elevate the level of MLC phosphorylation (*P < 0.05, 
Student’s unpaired t-test, n=3). Data are presented as mean ± SEM. Representative 
immunoblots of phospho- (green) and total- (red) MLC2 from three separate experiments in 
the absence or presence of PPTN.  
 
Figure 10. Effect of preconstriction with U46619 followed by relaxation with forskolin (1 
µM) on the responses to (A) UDP-glucose, (B) UTP in porcine pancreatic arteries. (A) 
Exposing the tissues to U46619 followed by forskolin significantly enhanced the contraction 
evoked by UDP-glucose (***P < 0.001, two-way ANOVA, F=54.34; n=8-13). Data are 
presented as mean ± SEM. (B) Exposing the tissues to U66619 followed by forskolin failed 
to affect the response to UTP. (C) Typical traces showing the effect of UDP-glucose on basal 
tone (inset) and after the tissues were preconstricted with U46619 and then relaxed with 
forskolin (main). 
 
 
Figure 11. Effect of UTP (1 mM), UDP-glucose 1 (mM) and MRS2690 (10 µM) on the 
cAMP concentrations in porcine pancreatic arteries exposed to U46619 followed by 
forskolin. UTP had no significant effect on cAMP level, while UDP-glucose and MRS2690 
reduced significantly the cAMP level (*P < 0.05, Student’s unpaired t-test, the response to 
UTP or UDP-glucose or MRS2690 vs their respective controls, n=4). Basal cyclic AMP level 
represents the level of cAMP in the absence of forskolin which was also significantly 
different to that in the presence of forskolin (*P < 0.05, Student’s unpaired t-test, n=4). Data 
are presented as mean ± SEM. 
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Supplementary information for the manuscript 
 
 
 
 Effect of endothelium removal and BQ123, an ETA receptor antagonist on contraction 
to UDP-glucose in porcine isolated pancreatic arteries 
The contraction to UDP-glucose was reduced in endothelium-denuded arteries, but BQ123 (1 
µM) did not induce any further reduction in endothelium-denuded arteries (Figure 1), 
although it reduced UDP-glucose contraction in endothelium-intact arteries. This showed that 
the contribution of endothelin-1, acting at ETA receptors, in UDP-glucose induced 
contraction is solely endothelium-dependent. 
 
Effect of BQ788, an ETB receptor antagonist, on contraction to UDP-glucose in porcine 
isolated pancreatic arteries 
To find out whether endothelin-1 (released as a result of UDP-glucose activating P2Y14 
receptors) acts at ETB receptor, the response to UDP-glucose was examined in the presence 
of BQ788 (1 µM). BQ788 failed to alter the contraction to UDP-glucose which showed that 
ETB receptor is not involved in the contraction evoked by UDP-glucose (Figure 2). 
 
Effect of MRS2578, a P2Y6 receptor selective antagonist, on responses to UDP, UDP-
glucose and MRS2690 in porcine isolated pancreatic arteries 
Responses to UDP-glucose, UDP and MRS2690 were characterised using a P2Y6 receptor 
selective antagonist MRS2578 (10 µM). The contraction evoked by UDP was unaffected at 
lower concentrations but was augmented at higher concentrations of UDP (**P < 0.01, n=8-
13) (Figure 3A), while MRS2578 did not alter the responses to UDP-glucose or MRS2690 
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(n=6-13) (Figure 3B, C). MRS2578 (10 µM) partly blocked contraction to UTP in porcine 
coronary arteries, confirming its effect in porcine vessels at this concentration (data not 
shown). 
 
Figure Legends 
 
Figure 1. Effect of BQ123 (1 µM) in endothelium-denuded arteries and the effect of 
endothelium removal on responses to UDP-glucose in U46619-preconstricted porcine 
pancreatic arteries. BQ123 in endothelium-denuded arteries did not induce further reduction 
of the contraction to UDP-glucose (***P < 0.001, two-way ANOVA, F= 8.149, 9.294; n=14). 
Data are presented as mean ± SEM.  
 
Figure 2. Effect of BQ788 (1 µM) on response to UDP-glucose in U46619-preconstricted 
porcine pancreatic arteries. BQ788 had no effect on the contraction to UDP-glucose (n=7-8). 
Data are presented as mean ± SEM.  
 
Figure 3. Effect of MRS2578 (10 µM) on responses to UDP, UDP-glucose and MRS2690 in 
U46619-preconstricted porcine pancreatic arteries. (A) MRS2578 enhanced significantly the 
contraction evoked by UDP (**P < 0.01, two-way ANOVA, F= 9.953; n=8-13). (B), (C) 
MRS2578 failed to alter the contraction to UDP-glucose and MRS2690 (n=6-13). Data are 
presented as mean ± SEM.  
Figure 4. Concentration-dependent contraction evoked by UDP-glucose, in porcine 
pancreatic arteries in the presence and absence of PPTN (1 µM) (***P < 0.001, two-way 
ANOVA, F= 24.37; n=12). 
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Editor 
 
We are grateful to the Editor and Reviewers for constructive comments on the manuscript. 
We have addressed all of the comments through further experimentation and through changes 
to the manuscript as detailed below.  
In view of these comments, we have carried out a number of major changes to the manuscript 
that we believe further improve the robustness of the data. In addition we have now added 
data showing the effect of UDP-glucose and MRS2690 on MLC2 phosphorylation in the 
presence and absence of PPTN, a selective high affinity antagonist of the P2Y14 receptor, to 
confirm that the ability of UDP-glucose and MRS2690 to elevate level of phosphorylated 
MLC2 occurred through P2Y14 receptors (Figure 9). As recommended by both Reviewers the 
immunostaining plus the western blotting experiments have been removed from the 
manuscript as well as from the supplementary information due to the lack of a negative 
control for the P2Y14 receptor (despite our best attempts to identify one); further details are 
below. 
 
Comments to the Author (REQUIRED): 
The authors answered most queries raised in a convincing fashion. The two expert referees 
however, point out that some valid concerns were not fully addressed in the revised version 
of the manuscript. 
 
1- The authors' answer as to why a Thromboxane analog was administered conjointly with 
the contractile UDP-Glucose (Methods page 22 of 62) is not fully satisfactory since UDP 
glucose alone is a vasoconstrictor of the vessel studied. Additional experiments should be 
performed only with the UDP-glucose as a contractile agonist. 
 
Further experiments were conducted to study the contraction to UDP-glucose at basal tone 
(by its own). As seen in Figure 1, UDP-glucose induced a contraction at basal tone, which 
was significantly inhibited in the presence of PPTN, a selective high affinity antagonist of 
P2Y14 receptor. These data are clearly very similar to the data obtained at raised tone 
(although at raised tone we can see any potential vasorelaxant responses and the contractile 
responses are greater). We have included a statement to this effect in the revised manuscript 
(Page 13), and the figure has been added to the Supplementary information (Figure 4). 
 
 
 
 
 
 
Figure 1. Concentration-
dependent contraction 
evoked by UDP-glucose, in 
porcine pancreatic arteries in 
the presence and absence of 
PPTN (1 µM) (***P < 0.001, 
two-way ANOVA, F= 24.37; 
n=12). 
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2- The second major concern is linked to lack of experimental evidences for the specificity 
characteristics of the P2Y14 receptor antibody used. Both reviewers expressed valid concerns 
on that subject and it is suggested to the authors to provide additional data on that specific 
issue. 
 
We have carried out a number of experiments to investigate the specificity characteristics of 
the P2Y14 receptor antibody used in the western blotting and immunostaining experiments. 
However, the outcomes were not very satisfactory and we were unable to obtain a cell or 
tissue which could act as a negative control in our study. We used HL60 (Human 
promyelocytic leukemia cells), SHSY5Y (human neuroblastoma cell line), SK-N-MC 
(Human Brain Neuroepithelioma Cells) and mouse thoracic aorta; all of these cells/tissues 
were reported not to express the mRNA of the P2Y14 receptor or to express it only at a low 
level. However, all of these cells showed bands, when the existence of P2Y14 receptor (at 
protein level) was investigated using immunoblotting experiments. Therefore, the western 
blotting experiments and the immunostaining experiments have been removed from the 
manuscript and from the supplementary information. 
  
 
3-Finally, as pointed out by one of the reviewers, '...all molecules need to be indicated by 
their correct chemical names...' on their first appearance in the text and subsequently replaced 
by the appropriate acronyms throughout the manuscript (i.e. Compound 2). 
 
We have revised the nomenclature of the receptors and drugs to conform to BJP's Guide to 
Receptors and Channels. All correct chemical names have now been added in the text on their 
first appearance. Compound 2 has now been replaced by its synonym (PPTN) (Barrett MO, 
Sesma JI, Ball CB, Jayasekara PS, Jacobson KA, Lazarowski ER, et al. (2013). Human 
Neutrophils. Molecularpharmacology; 
http://www.ncbi.nlm.nih.gov/pubmed/23592514. 
 
 
 
 
Reviewers' Comments to Author: 
 
Reviewer: 2 
Comments to the Author 
BJP – Novel vasocontractile role of the P2Y14 receptor: characterisation of its signalling in 
porcine isolated pancreatic arteries. 
 
A great effort to respond the critiques and to ameliorate the paper was done. Few more 
comments are appended below: 
 
1. Although the authors have tempered their data interpretation about the Abs this is not 
sufficient. The authors should carry out experiments with positive control proteins from both 
human and porcine expressing tissues, or recombinant proteins etc. together with negative 
controls. If the authors cannot provide this information they cannot present these data in the 
paper, this includes also the supplementary data. Either show the controls to convince about 
the specificity of the Abs, (the ones presented in Fig 11 are not sufficient unless you would 
already know the level of expression in those tissues), or delete all those data. 
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We have carried out a number of experiments to investigate the specificity characteristics of 
the P2Y14 receptor antibody used in the western blotting and immunostaining experiments. 
However, the outcomes were not very satisfactory and we were unable to obtain a cell or 
tissue which could act as a negative control in our study. We used HL60 (Human 
promyelocytic leukemia cells), SHSY5Y (human neuroblastoma cell line), SK-N-MC 
(Human Brain Neuroepithelioma Cells) and mouse thoracic aorta; all of these cells/tissues 
were reported not to express the mRNA of the P2Y14 receptor or to express it only at a low 
level. However, all of these cells showed bands, when the existence of P2Y14 receptor (at 
protein level) was investigated using immunoblotting experiments. Therefore, the western 
blotting experiments and the immunostaining experiments have been removed from the 
manuscript and from the supplementary information. 
 
  
 
 
 
2. The description of Fig 1 B. is not clear and needs further details. How/When was added the 
“same” agonist etc.  
 
 
We have now clarified the description of Figure 1B. The response to UDP-glucose (the 
control) was studied in the presence of UDP-glucose and UDP (both agonists at P2Y14 
receptors), to find out whether the response to UDP-glucose (the control) would desensitise in 
the presence of P2Y14 receptor agonists. Both agonists (UDP-glucose or UDP) were added 10 
min prior to the addition of U46619 (as stated in the method section page 8, and now in the 
legend) to investigate desensitisation of the contraction to UDP-glucose in the presence of 
P2Y14 receptor agonists. 
 
 
Reviewer: 1 
Comments to the Author 
The new data and modifications of the text have substantively improved this manuscript. 
Several concerns remain that should be addressed. 
 
1. This reader remains concerned that the authors’ insistence on calling the molecule 
compound 2 will introduce unnecessary confusion in the literature. New molecular identities 
in medicinal chemistry papers are by convention referred to by numbers beginning with 1 and 
in the paper by Robichaud et al (Bioorg and Med Chem Lett 21:4366-4368, 2011) there were 
11 such derivatives (including one called compound 2) referred to by numbers. However, in 
the two preceding papers on P2Y14 antagonists from this research group (Guay et al Biorg. 
Med. Chem Lett. 21:2832-2835, 2011 and Gauthier et al 21:2836-2839, 2011) there was also 
a “compound 2” which in fact referred to two entirely different molecules from the one that 
the authors in this submitted paper are calling compound 2. Why not unambiguously call it by 
its chemical name, which is 4-((piperidin-4-yl)-phenyl)-7-(4-trfluoromethyl)-phenyl)-2-
napthoic acid? 
 
We have now changed the name of the P2Y14 selective antagonist to PPTN according to the 
report of (Barrett MO, Sesma JI, Ball CB, Jayasekara PS, Jacobson KA, Lazarowski ER, et 
al. (2013). Human Neutrophils. Molecularpharmacology; 
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http://www.ncbi.nlm.nih.gov/pubmed/23592514, in which they used exactly the same 
compound/structure that we used in our study. In addition we have added the correct 
chemical name to the manuscript, page 6.  
 
 
2. Page 19 bottom line. The information in parentheses adds confusion---Compound 2 is in 
fact a 4,7-disubstituted naphthoic acid derivative but this provides no information about 
which derivative this is—again the molecule needs to be indicated by its correct chemical 
name. 
 
The correct structure is now stated in the manuscript according to the report of (Barrett MO, 
Sesma JI, Ball CB, Jayasekara PS, Jacobson KA, Lazarowski ER, et al. (2013). Human 
Neutrophils. Molecularpharmacology; 
http://www.ncbi.nlm.nih.gov/pubmed/23592514,.The correct structure is 4-(4-(Piperidin-4-
yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoic acid, and has now been added to page 6 
of the manuscipt. 
 
3. The addition of new cyclic AMP data (Figure 10) greatly strengthens the mechanistic story 
developed here. However, basal cyclic AMP levels in the absence of added forskolin need to 
be added to the figure. 
 
We have now added a column which represents the level of basal cyclic AMP in the absence 
of forskolin (Figure 11, Page 30) and explained it in the legend.   
 
 
4. The authors’ arguments that the antibody is detecting the P2Y14 receptor are not 
convincing. That a signal is not seen in the absence of primary antibody tells nothing about 
whether this antibody detects natively expressed P2Y14 receptor or not. The paper provides a 
very strong pharmacological argument for the existence of functional P2Y14 receptors in 
porcine pancreatic artery contraction, but inclusion of the antibody data would in the opinion 
of this reader weaken the quality of this manuscript. 
 
We have carried out a number of experiments to investigate the specificity characteristics of 
the P2Y14 receptor antibody used in the western blotting and immunostaining experiments. 
However, the outcomes were not very satisfactory and we were unable to obtain a cell or 
tissue which could act as a negative control in our study. We used HL60 (Human 
promyelocytic leukemia cells), SHSY5Y (human neuroblastoma cell line), SK-N-MC 
(Human Brain Neuroepithelioma Cells) and mouse thoracic aorta; all of these cells/tissues 
were reported not to express the mRNA of the P2Y14 receptor or to express it only at a low 
level. However, all of these cells showed bands, when the existence of P2Y14 receptor (at 
protein level) was investigated using immunoblotting experiments. Therefore, the western 
blotting experiments and the immunostaining experiments have been removed from the 
manuscript and from the supplementary information. 
  
 
5. The Schulte and Fredholm, 2003 citation (top of page 35) on adenosine receptors should be 
deleted. 
 
Thank you. It has now been deleted. 
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